Forsøg med 225Ac-DOTATATE (RYZ101) alene og med Pembrolizumab i forsøgspersoner med ER+, HER2-negative, ikke-operable eller metastatisk brystkræft, der udtrykker SSTR'er (TRACY-1)
Fase 1b/2 åbent forsøg med 225Ac-DOTATATE (RYZ101) alene og i kombination med Pembrolizumab i forsøgspersoner med østrogenreceptorpositiv (ER+), human epidermal vækstfaktorreceptor 2 (HER2)-negativ, lokalt avanceret og uoperabel Brystkræft, der udtrykker somatostatinreceptorer (SSTR'er) og fremskridt efter antistof-lægemiddelkonjugater og/eller kemoterapi (TRACY-1)
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
Studieoversigt
Status
Status
Betingelser
Betingelser
- Avanceret brystkræft
- Metastatisk brystkræft
- Østrogenreceptor-positiv brystkræft
- HER2-negativ brystkræft
- ER+ brystkræft
- Knoglemetastaser hos forsøgspersoner med avanceret brystkræft
- ER-positiv HER2-negativ brystkræft
- Hormonfølsom metastatisk brystkræft
- Metastatisk brystkræft med knogleinvolvering
- Hormone-Sensitive Breast Cancer
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: RayzeBio Clinical Trials
- Telefonnummer: 1-619-657-0057
- E-mail: clinicaltrials@rayzebio.com
Studiesteder
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Rekruttering
- Research Facility
-
Kontakt:
- Site Contact
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
Toronto, Ontario, Canada, M5G 2M9
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
-
Quebec
-
Québec, Quebec, Canada, G1S 4L8
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
-
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85054
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
-
California
-
Irvine, California, Forenede Stater, 92618
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
San Diego, California, Forenede Stater, 92093
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
Santa Monica, California, Forenede Stater, 90404
- Rekruttering
- Research Facility
-
Kontakt:
- Site Contact
-
-
Colorado
-
Longmont, Colorado, Forenede Stater, 80504
- Rekruttering
- Research Facility
-
Kontakt:
- Site Contact
-
-
Florida
-
Jacksonville, Florida, Forenede Stater, 32224
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Rekruttering
- Research Facility
-
Kontakt:
- Site Contact
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48202
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
-
Minnesota
-
Maplewood, Minnesota, Forenede Stater, 55109
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
Rochester, Minnesota, Forenede Stater, 55905
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63130
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68124
- Rekruttering
- Research Facility
-
Kontakt:
- Site Contact
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87109
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
-
New York
-
Buffalo, New York, Forenede Stater, 14203
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
New York, New York, Forenede Stater, 10016
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
New York, New York, Forenede Stater, 10021
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
Pittsburgh, Pennsylvania, Forenede Stater, 15213
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75246
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
Houston, Texas, Forenede Stater, 77024
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84132
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
-
Virginia
-
Norfolk, Virginia, Forenede Stater, 23502
- Ikke rekrutterer endnu
- Research Facility
-
Kontakt:
- Site Contact
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98109
- Rekruttering
- Research Facility
-
Kontakt:
- Site Contact
-
-
-
-
Seoul
-
Seoul, Seoul, Sydkorea, 03080
- Aktiv, ikke rekrutterende
- Research Facility
-
Seoul, Seoul, Sydkorea, 05505
- Aktiv, ikke rekrutterende
- Research Facility
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria
Subjects must meet all the following criteria for enrollment in the study:
-
Histologically confirmed, ER+, HER2-negative, locally advanced and unresectable or metastatic breast cancer not amenable to treatment with curative intent.
-
Adequate renal, hematologic, and hepatic function
-
Additional inclusion criteria for Monotherapy arm:
- Measurable disease with at least 80% SSTR-positive lesions by SSTR-PET imaging
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2
- Documented radiologic progression after at least 2 and no more than 4 prior chemotherapy or ADC regimens in the metastatic setting
-
Additional inclusion criteria for ET Combination arms:
- Prior treatment with CDK4/6 inhibitors in combination with endocrine therapy in the advanced or metastatic setting.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1
- Bone only or bone dominant disease. At least 1 bone lesion must be SSTR-positive on SSTR-PET imaging. For bone dominant disease, at least 50% of soft tissue measurable lesions must be SSTR-positive on SSTR-PET imaging. At least one bone lesion must be positive on both SSTR-PET and on FDG-PET imaging
- Brain metastases are allowed if definitively treated and clinically stable as confirmed by interval imaging
Exclusion Criteria
Subjects who meet any of the following criteria will be excluded from the study:
-
Prior radiopharmaceutical therapy, including radioembolization.
-
Any toxicities from prior treatments that have not recovered to CTCAE Grade ≤1, except for alopecia.
-
Significant cardiovascular disease
-
Known active uncontrolled or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, spinal cord compression, or leptomeningeal disease.
-
History of hypersensitivity or allergy to 225Ac, 68Ga, 64Cu, octreotate, or any of the excipients of DOTATATE imaging agents.
-
Prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the study safety or efficacy assessments.
-
Pregnancy or breastfeeding
-
Additional exclusion criteria for ET Combination arms:
- Presence of liver metastases or symptomatic metastatic visceral disease
- Prior PARPi exposure or are candidates for PARPi per local guidelines
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Monotherapy Dose Escalation
Escalating doses of RYZ101 administered intravenously (IV) |
Ac-225 |
|
Eksperimentel: Endocrine Therapy Combination Dose Escalation and Expansion
RYZ101 in combination with investigator's choice of standard of care endocrine therapy |
Ac-225 Investigator's choice of endocrine therapy, such as, anastrozole, elacestrant, exemestane, fulvestrant, imlunestrant, letrozole, tamoxifen, or vepdegestrant |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Dose Escalation
Tidsramme: 6 weeks of RYZ101 treatment
|
Incidence rate of DLTs during the first 6 weeks of RYZ101 treatment |
6 weeks of RYZ101 treatment
|
|
Endocrine Therapy Combination Dose Escalation
Tidsramme: [Time Frame: 6 weeks of study treatment]
|
Incidence rate of DLTs during the first 6 weeks of study treatment |
[Time Frame: 6 weeks of study treatment]
|
|
Endocrine Therapy Combination Dose Escalation
Tidsramme: Up to approximately 5 years after the last subject has completed RYZ101 treatment
|
Incidence and severity of treatment emergent AEs by NCI-CTCAE v5.0 |
Up to approximately 5 years after the last subject has completed RYZ101 treatment
|
|
Endocrine Therapy Combination Dose Escalation and Expansion
Tidsramme: Up to approximately 5 years after the last subject has completed RYZ101 treatment
|
Progression Free Survival, defined as the time between first dose of study treatment and progression or death, as assessed by the investigator per RECIST v1.1 criteria |
Up to approximately 5 years after the last subject has completed RYZ101 treatment
|
|
Endocrine Therapy Combination Dose Escalation and Expansion
Tidsramme: Up to approximately 5 years after the last subject has completed RYZ101 treatment
|
Time from the first dose of study treatment to first occurrence of Skeletal Related Events |
Up to approximately 5 years after the last subject has completed RYZ101 treatment
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Petrus de Jong, MD, PhD, RayzeBio, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- RYZ101-201
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .